Legal & General Group Plc Grows Stock Holdings in CVS Health Corporation $CVS

Posted by Brian Himes on May 25th, 2026

Legal & General Group Plc raised its position in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 0.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 9,309,182 shares of the pharmacy operator’s stock after buying an additional 31,249 shares during the period. Legal & General Group Plc’s holdings in CVS Health were worth $738,777,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of CVS Health by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock valued at $9,579,508,000 after buying an additional 1,824,424 shares during the last quarter. Capital World Investors lifted its position in shares of CVS Health by 2.1% during the third quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock valued at $5,155,380,000 after buying an additional 1,419,575 shares during the last quarter. State Street Corp lifted its position in shares of CVS Health by 0.3% during the third quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock valued at $4,443,357,000 after buying an additional 149,701 shares during the last quarter. Capital International Investors lifted its position in shares of CVS Health by 1.1% during the third quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock valued at $2,012,347,000 after buying an additional 302,499 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of CVS Health by 3.2% during the third quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after buying an additional 760,579 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by corporate insiders.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: Bernstein reiterated an Outperform rating and raised its price target on CVS to $106, saying the company is well positioned for a Medicare Advantage turnaround. Bernstein Sees CVS Well Positioned for Medicare Advantage Turnaround
Positive Sentiment: Glenview Capital said CVS has delivered about an 80% total return since May 2024, reinforcing confidence in the company’s operational turnaround and long-term investment case. Glenview Capital Issues Statement on CVS Health
Neutral Sentiment: CVS announced a collaboration with America250 to support the nation’s 250th anniversary celebration, a brand-building move that is unlikely to have a major near-term effect on earnings. CVS Health Collaborates With America250 To Support the Nation’s 250th Anniversary Celebration
Neutral Sentiment: Recent community and philanthropic announcements, including support for military families and senior housing, add to CVS’s public-facing story but are not likely to move the shares materially on their own. CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
Negative Sentiment: Three major hospital systems, including affiliates tied to Mount Sinai, the University of Michigan, and the University of Kansas, sued CVS, alleging it siphoned about $250 million from the 340B drug program through reduced reimbursements. Hospitals sue CVS for allegedly siphoning $250M in 340B funds
Negative Sentiment: Separate reports say hospital systems are expanding the 340B dispute, raising the risk of more litigation, settlement costs, and reputational pressure for CVS’s pharmacy-benefit operations. CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment
Negative Sentiment: Director Larry Robbins disclosed several large stock sales over the past few days, including a roughly $187 million sale, which can weigh on investor sentiment even though he still owns a large stake. SEC Form 4 filing

CVS Health Stock Performance

Shares of CVS Health stock opened at $93.24 on Monday. The firm has a market capitalization of $118.97 billion, a P/E ratio of 41.08, a PEG ratio of 0.91 and a beta of 0.60. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The company has a 50 day moving average price of $80.38 and a 200 day moving average price of $79.09. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43.

CVS Health (NYSE:CVS – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. CVS Health’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the firm posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts expect that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.9%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio is 117.18%.

Wall Street Analysts Forecast Growth

Several analysts have commented on CVS shares. Wells Fargo & Company increased their price target on shares of CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. TD Cowen increased their price target on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Argus increased their price objective on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Sanford C. Bernstein increased their price objective on shares of CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a research report on Tuesday, May 12th. Finally, Robert W. Baird increased their price objective on shares of CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $98.68.

Check Out Our Latest Research Report on CVS

CVS Health Company Profile

(Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.